Other News To Note
BioCryst Pharmaceuticals Inc., of Research Triangle Park, N.C., reported that in response to recent events including the termination of its planned merger with San Francisco-based Presidio Pharmaceuticals Inc. and setbacks in their peramivir and BCX5191 programs, as well as the delay in their BCX4161 program, it is restructuring and implementing a focused strategy to advance its hereditary angioedema (HAE) and antiviral programs.
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter